Form 1-U Nok Therapeutics, Inc. For: May 28

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 1-U

 

CURRENT REPORT PURSUANT TO REGULATION A

 

Date of Report (Date of earliest event reported) May 28, 2026

 

NOK Therapeutics, Inc.

 

Florida

99-3344253

 

2009 MacKenzie Way, Suite 100

Cranberry Township, Pennsylvania 16066

888-691-5839

 

Title of each class of securities issued pursuant to Regulation A:

Common Stock

 

 

  

Item 7. Departure of Certain Officers

 

On May 28, 2026, Robert Lewis, President and Principal Executive Officer, stepped down from his position as President and Director of NOK Therapeutics, Inc., effective immediately.

 

Mr. Lewis’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

 

 

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

(Exact name of issuer as specified in its charter)		NOK Therapeutics, Inc.
		/s/ Brian Cogley
By (Signature and Title)		Brian Cogley
		Chief Financial Officer
Date: June 3, 2026

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• DentScribe Introduces AI Patient Profiles and Treatment Coordinator Intelligence for DSOs and Multi-Location Dental Groups
• Kimball Electronics Acquires European-Based Medical CDMO, Helvoet Polymer Technologies B.V.
• Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division